Top Reasons Argentine Medical Device Registrations Get Rejected

1. Key takeaways

According to industry practice (a practical estimate), the high-frequency failure reasons in submissions by Chinese companies in Argentina concentrate in seven places:

1. Incomplete certification chain for the CFS / authorization declaration — missing Apostille certification, missing translation, or exceeding the 2-year validity period;
2. Missing label elements — no importer information, no registration number, non-standard Spanish;
3. ISO 13485 certificate scope mismatched with the products submitted, or the certificate near expiry;
4. Poor Spanish quality of the technical documentation, with terminology errors triggering deficiency requests;
5. Slow response of the local license holder, where delayed deficiency responses repeatedly pause the review clock;
6. Classification errors — especially for products containing software, medicinal substances, or nanomaterials;
7. Insufficient GMP evidence triggering a factory inspection, whose scheduling cannot be controlled.

Each of the seven has a distinct cost profile, but they share one feature: five of them are fully visible before submission, which means the majority of rejections are foreseeable and preventable with preparation discipline rather than regulatory goodwill.

2. Legal basis

3. Expert insights

Insight 1: Five of the seven reasons (items 1, 2, 3, 4, 6) are formal and preparation problems that can be fully avoided before submission. The genuinely substantive difficulties are only item 5 (holder responsiveness) and item 7 (factory inspection scheduling). This means most rejections are not capability problems but process management problems. A company that accepts this diagnosis shifts its investment from arguing with the regulator to tightening its own pre-submission workflow — a far cheaper and faster improvement.

Insight 2: Classification errors, item 6, have risen markedly since 2025. The reason is that the principal regulation changed from 2318/02 to GMC 25/21, whose 22 classification rules contain dedicated rules for products containing software, medicinal substances, and nanomaterials. Companies that carry over classification conclusions made under the old regulation face a substantially higher probability of rejection, because the new rules ask questions the old conclusions never addressed.

Insight 3: The common remedy for the five formal problems is a mock formal review before submission. ANMAT’s formal review after acceptance takes approximately 10 consecutive days and examines only completeness and formal correctness. A company that self-checks against the same standard can drive the rejection probability for items 1 through 4 close to zero. The mock review needs no regulator interaction: it is a checklist executed against the dossier itself, ideally by someone who did not prepare the documents.

4. Practical recommendations

1. Build a seven-item pre-submission self-check table. Tick each item in turn and do not submit until every item passes, with certification, translation, and validity as the three priority checks.
2. Start the certification chain first and re-verify it last. The three steps for the CFS and authorization declaration — issuance, certification, translation — start at project launch, and their validity periods are re-checked immediately before submission.
3. Perform a written comparison of the ISO 13485 certificate scope. Compare the certificate scope text against the submitted products one by one, and where necessary request a clarification letter from the certification body.
4. Agree deficiency-response time limits in the license-holding agreement. This converts item 5 from a matter of cooperation into a contractual obligation with enforceable deadlines.
5. Prepare an independent classification rationale for software-containing, medicinal, and nanomaterial products. Do not accept reasoning by analogy; where necessary, submit an official consultation through TAD first.

5. Verification checklist

• □ The seven-item pre-submission self-check completed and ticked item by item
• □ The certification chain for the CFS and authorization declaration complete in all three steps and within validity
• □ Label elements checked item by item against Annex IV of GMC 25/21
• □ ISO 13485 certificate scope compared in writing against the submitted products
• □ Spanish technical documentation translated and proofread by regulatory translators
• □ Deficiency-response time limits agreed in the license-holding agreement
• □ Independent classification rationale completed for software-containing, medicinal, and nanomaterial products

Regulatory information verified as of October 29, 2026.

One final observation ties the seven reasons together: they interact. An incomplete certification chain (item 1) often co-occurs with a slow holder (item 5), because the same local entity that holds the certificate must also respond to deficiency requests — and each paused review multiplies the chance that a 2-year CFS validity period expires mid-review, restarting item 1 from zero. Likewise, classification errors (item 6) can trigger GMP scrutiny (item 7) when the claimed class implies manufacturing controls the dossier never evidenced. The self-check table is therefore not a list of seven independent gates but a model of how rejections compound, and the discipline of clearing all seven before submission is what keeps one formal defect from escalating into a full cycle of re-filing under GMC/RES 25/21 and Disposición 64/2025.

In Argentina, GRZAN operates a wholly-owned subsidiary that can serve as the registration holder and importer for foreign manufacturers, directly handling classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the dynamics of regulatory authorities across countries on an ongoing basis. All external content follows the drafting standard of conclusions first, traceable bases, and verifiable figures. For an Argentina or MERCOSUR market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.